Novel lipid A mimetics derived from pentaerythritol: Synthesis and their potent agonistic activity

Tetrahedron

Volumn 58, Issue 43, 2002, Pages 8833-8842

  Jiang, Zi Hua ^a   Budzynski, Wladyslaw A ^a   Skeels, Lisa N ^a   Krantz, Mark J ^a   Koganty, R Rao ^a  

^a Biomira Inc   (Canada)

Author keywords

Cytokine; Immunostimulatory adjuvant; Lipid A mimetic; Molecular vaccine; Pentaerythritol

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; LIPID A; PENTAERYTHRITOL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; ISOMER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA MINNESOTA; T LYMPHOCYTE ACTIVATION;

SALMONELLA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR MINNESOTA;

EID: 0037152579     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(02)01067-0     Document Type: Article

References (41)

1. Takada H., Kotani S. CRC Crit. Rev. Microbiol. 16:1989;477-523.
2. Rietschel E.T., Brade H., Holst O., Brade L., Müller-Loennies S., Mamat U., Zähringer U., Beckmann R., Seydel U., Brandenburg K., Ulmer A.J., Mattern T., Heine H., Schletter J., Hauschildt S., Loppnow H., Schönbeck U., Flad H.-D., Schade U.F., Di Padova F., Kusumoto S., Schumann R.R. Curr. Top. Microbiol. Immunol. 216:1996;39-81.
3. Schromm A.B., Brandenburg K., Loppnow H., Zähringer U., Rietschel E.T., Carroll S.F., Koch M.H., Kusumoto S., Seydel U. J. Immunol. 161:1998;5464-5471.
4. Schromm A.B., Brandenburg K., Loppnow H., Moran A.P., Koch M.H.J., Rietschel E.T., Seydel U. Eur. J. Biochem. 267:2000;2008-2013.
5. Seydel U., Oikawa M., Fukase K., Kusumoto S., Brendenburg K. Eur. J. Biochem. 267:2000;3032-3039.
6. Heldwein K.A., Golenbock D.T., Fenton M.J. Mod. Asp. Immunobiol. 1:2001;249-252.
7. (a) Krutzik S.R., Sieling P.A., Modlin R.L. Curr. Opin. Immunol. 13:2001;104-108.
8. (b) Akira S., Takeda K., Kaisho T. Nat. Immunol. 2:2001;675-680.
9. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., Takeda K., Akira S. J. Immunol. 162:1999;3749-3752.
10. Kutuzova G.D., Albrecht R.M., Erickson C.M., Qureshi N. J. Immunol. 167:2001;482-489.
11. (a) Matsuura M., Yamamoto A., Kojima Y., Homma J.Y., Kiso M., Hasegawa A. J. Biochem. 98:1985;1229-1237.
12. (b) Ueda H., Yamazaki M. J. Immunother. 20:1997;65-69.
13. (c) Matsuura M., Kiso M., Hesagawa A. Infect. Immun. 67:1999;6286-6292.
14. (d) Lynn W.A., Golenbock D.T. Immunol. Today. 13:1992;271-276.
15. (a) Bulusu M.A.R.C., Waldstätten P., Hildebrandt J., Schütze E., Schulz G. J. Med. Chem. 35:1992;3463-3469.
16. (b) Eustache J., Grob A., Retscher H. Carbohydr. Res. 251:1994;251-267.
17. (c) Johnson D.A., Sowell C.G., Johnson C.L., Livesay M.T., Keegan D.S., Rhodes M.J., Ulrich J.T., Ward J.R., Cantrell J.L., Brookshire V.G. Bioorg. Med. Chem. Lett. 9:1999;2273-2278.
18. (d) Ikeda K., Asahara T., Achiwa K. Chem. Pharm. Bull. 41:1993;1879-1881.
19. (e) Lien E., Chow J.C., Hawkins L.D., McGuinness P.D., Miyake K., Espeviks T., Gusovsky F., Golenbock D.T. J. Biol. Chem. 276:2001;1873-1880.
20. Qureshi N., Mascagni P., Ribi E., Takayama K. J. Biol. Chem. 260:1985;5271-5278.
21. Johnson D.A., Keegan D.S., Sowell C.G., Livesay M.T., Johnson C.L., Taubner L.M., Harris A., Myers K.R., Thompson J.D., Gustafson G.L., Rhodes M.J., Ulrich J.T., Ward J.R., Yorgensen Y.M., Cantrell J.L., Brookshire V.G. J. Med. Chem. 42:1999;4640-4649.
22. ® has been claimed to be hexaacyl substituted. On the other hand, the lipid A product provided by Avanti Polar Lipids, Inc., does not undergo selcetive hydrolysis of this 3-O-acyl group and its major component has been claimed to be heptaacyl substituted. Our experimental results (data not shown) indicate that this 3-O-acyl group does not have much effect on the toxicity profile of lipid A product from S. minnesota R595. For more informations, please see (a) Johnson D.A., Keegan D.S., Sowell C.G., Livesay M.T., Johnson C.L., Taubner L.M., Harris A., Myers K.R., Thompson J.D., Gustafson G.L., Rhodes M.J., Ulrich J.T., Ward J.R., Yorgensen Y.M., Cantrell J.L., Brookshire V.G. J. Med. Chem. 42:1999;4640-4649 (b) Ulrich J.T., Myers K.R. Powell M.F., Newman M.J., Vaccine Design: The Subunit and Adjuvant Approach. 1995;495-524 Plenum, New York.
23. Jiang Z.-H., Bach M.V., Budzynski W.A., Krantz M.J., Koganty R.R., Longenecker B.M. Bioorg. Med. Chem. Lett. 12:2002;2193-2196.
24. Newkome G.R., Mishra A., Moorefield C.N. J. Org. Chem. 67:2002;3957-3960.
25. Farcy N., Muynck H.D., Madder A., Hosten N., Clercq P.J.D. Org. Lett. 3:2001;4299-4301.
26. Dunn T.J., Neumann W.L., Gogic M.M., Woulfe S.R. J. Org. Chem. 55:1990;6368-6373.
27. 3-DMF reaction condition with tosylate. Patel A., Lindhorst T.K. Eur. J. Org. Chem. 2002;79-86.
28. Schmidt R.R., Kinzy W. Adv. Carbohydr. Chem. Biochem. 50:1994;21-123.
29. Dullenkopf W., Castro-Palomino J.C., Manzoni L., Schmidt R.R. Carbohydr. Res. 296:1996;135-147.
30. Liu W.-C., Oikawa M., Fukase K., Suda Y., Kusumoto S. Bull. Chem. Soc. Jpn. 72:1999;1377-1385.
31. Shüle G., Ziegler T. Liebigs Ann. 1996;1599-1607.
32. Kiso M., Tanaka S., Fujita M., Fujishima Y., Ogawa Y., Hasagawa A. Carbohydr. Res. 162:1987;247-256.
33. Garegg P.J. Pure Appl. Chem. 56:1984;845.
34. Bannwarth W., Trzeciak A. Helv. Chim. Acta. 70:1987;175-186.
35. Boullanger P., Chatelard P., Descotes G., Kloosterman M., Van Boom H. J. Carbohydr. Chem. 5:1986;541-559.
36. Heufler C., Koch F., Stanzl U., Topar G., Wysocka M., Trinchieri G., Enk A., Steinmann R.M., Romani N., Schuler G. Eur. J. Immunol. 26:1996;659-668.
37. Lutz M.B., Kukutsch N., Ogilvie A.L.J., Rossner S., Koch F., Romani N., Schuler G. J. Immunol. Methods. 223:1999;77-99.
38. For examples of lipid A product from S. minnesota R595 being incorporated into liposomal vaccine as an adjuvant, please see (a) Richards R.L., Rao M., Wassef N.M., Glenn G.M., Rothwell S.W., Alving C.R. Infect. Immun. 1998;2859-2865 (b) Samuel J., Budzynski W.A., Reddish M.A., Ding L., Zimmermann G.L., Krantz M.J., Koganty R.R., Longenecker B.M. Int. J. Cancer. 75:1998;295-302.
39. For examples of lipid A product from S. minnesota R595 being incorporated into liposomal vaccine as an adjuvant, please see (a) Richards R.L., Rao M., Wassef N.M., Glenn G.M., Rothwell S.W., Alving C.R. Infect. Immun. 1998;2859-2865 (b) Samuel J., Budzynski W.A., Reddish M.A., Ding L., Zimmermann G.L., Krantz M.J., Koganty R.R., Longenecker B.M. Int. J. Cancer. 75:1998;295-302.
40. Palmer M., Parker J., Modi S., Butts C., Smylie M., Meikle A., Kehoe M., MacLean G., Longenecker B.M. Clin. Lung Cancer. 3:2001;49-57.
41. Moingeon P., Haensler J., Lindberg A. Vaccine. 19:2001;4363-4372.